Highland Therapeutics to Present at Cowen and Company Healthcare Conference
TORONTO, Feb. 25, 2014 /CNW/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that the Company's President and Chief Executive Officer, David Lickrish, will present at the 34th Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Highland's presentation is scheduled for Monday, March 3, 2014 at 11:00am EST.
A live webcast of the presentation can be accessed by visiting www.highlandtherapeutics.com. The webcast will be archived on the Company's website for 30 days.
Mr. Lickrish will provide the investment community with an update on the clinical development of HLD-200 and HLD-100, Highland's novel formulations of methylphenidate and amphetamine, respectively, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). HLD-200 and HLD-100 are designed to be taken at bedtime, to provide clinically meaningful control of symptoms of ADHD upon wakening and throughout the day.
Having recently completed an End-of-Phase II meeting with the FDA, Highland plans to initiate a Phase III trial with HLD-200 in the second quarter of 2014. Data are expected in the third quarter of 2014.
Methylphenidate is currently sold under the brand name Concerta by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company), Ritalin/Ritalin LA by Novartis Pharmaceuticals Corporation and Quillivant XR by Pfizer Inc. Amphetamine-based products include Adderall XR and Vyvanse (both products of Shire plc).
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is an emerging pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technologies to optimize the delivery of previously approved drug products. The Company's lead products, HLD-100 and HLD-200, are novel formulations of the psychostimulants (amphetamine and methylphenidate, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease - the lack of symptom control during the early morning routine. The clinically meaningful benefits of Highland's approach are targeted at helping ADHD patients and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District's Life Sciences and Healthcare practice, which provides advisory services and support to help Ontario life sciences companies grow and commercialize their businesses.
This press release contains forward-looking information, which reflects Highland's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Highland Therapeutics Inc.For further information:
please contact Nelson F. Isabel at (647) 260-7875.